Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T00:15:18.789Z Has data issue: false hasContentIssue false

Chapter 39 - Autoimmune Disease in Pregnancy (Content last reviewed: 23rd July 2019)

from Section 5 - Late Pregnancy – Maternal Problems

Published online by Cambridge University Press:  15 November 2017

By
T. Flint Porter  and
D. Ware Branch
Edited by
David James ,
Philip Steer ,
Carl Weiner ,
Bernard Gonik  and
Stephen Robson
David James
Affiliation:
University of Nottingham
Philip Steer
Affiliation:
Imperial College London
Carl Weiner
Affiliation:
University of Kansas
Bernard Gonik
Affiliation:
Wayne State University, Detroit
Stephen Robson
Affiliation:
University of Newcastle
Get access

Summary

The immune system’s remarkable ability to protect the body from invasion by foreign pathogens stems from its capacity to distinguish biologic “self” from “nonself.” An aberration in this normally well-regulated process leads to so-called autoimmunity, in which immune effector cells are directed against “self” tissues. Persistent abnormal immunologic activation results in autoimmune disease, each type characterized by a typical pattern of clinical signs and symptoms and confirmed by the presence of immune effector cells, usually autoantibodies. In some autoimmune conditions, serologically detected autoantibodies play an active role in tissue damage, while in others they serve only to confirm the existence of an autoimmune process. The pathophysiology leading to autoimmunity likely involves a failure of complex regulatory mechanisms, which normally control activation and deactivation of the immune system. Recent investigations suggest that full expression of autoimmune disease depends on a combination of environmental, genetic, and host factors.

Type
Chapter
Information
High-Risk Pregnancy
Management Options
 , pp. 1107 - 1158
Publisher: Cambridge University Press
First published in: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beeson, PB. Age and sex associations of 40 autoimmune diseases. Am J Me 1994; 96: 457–62.Google Scholar
Ansar Ahmed, S, Dauphinee, MJ, Talal, N. Effects of short-term administration of sex hormones on normal and autoimmune mice. J Immunol 1985; 134: 204–10.Google Scholar
Jungers, P, Dougados, M, Pelissier, C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618–23.Google Scholar
Mackworth-Young, CG, Parke, AL, Morley, KD, Fotherby, K, Hughes, GR. Sex hormones in male patients with systemic lupus erythematosus: a comparison with other disease groups. Eur J Rheumatol Inflamm 1983; 6: 228–32.Google Scholar
Lockshin, MD, Qamar, T, Druzin, ML. Hazards of lupus pregnancy. J Rheumatol 1987; 14 (Suppl 13): 214–17.Google Scholar
Rahman, P, Gladman, DD, Urowitz, MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol 1998; 25: 1526–30.Google Scholar
Guller, S, Kong, L, Wozniak, R, Lockwood, CJ. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab 1995; 80: 2244–50.Google Scholar
Lockwood, CJ, Radunovic, N, Nastic, D, et al. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J Perinat Med 1996; 24: 243–51.Google Scholar
Buchanan, NM, Toubi, E, Khamashta, MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486–8.Google Scholar
Khamashta, MA, Buchanan, NM, Hughes, GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus 1996 ;5 (Suppl 1): S65–6.Google Scholar
Motta, M, Tincani, A, Faden, D, Zinzini, E, Chirico, G. Antimalarial agents in pregnancy. Lancet 2002; 359: 524–5.CrossRefGoogle ScholarPubMed
Costedoat-Chalumeau, N, Amoura, Z, Duhaut, P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207–11.Google Scholar
Hart, CW, Naunton, RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964; 80: 407–12.Google Scholar
Nylander, U. Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh) 1967; (Suppl 92): 91–71.Google Scholar
Levy, RA, Vilela, VS, Cataldo, MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401–4.CrossRefGoogle ScholarPubMed
Daniel, S, Matok, I, Gorodischer, R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012; 39: 2163–9.Google Scholar
Schisterman, EF, Silver, RM, Lesher, LL, et al. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet 2014; 384: 29–36.Google Scholar
Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA, Group, PC. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791–8.Google Scholar
Hammers, AL, Sanchez-Ramos, L, Kaunitz, AM. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. Am J Obstet Gynecol 2015; 212: 505.e501–13.Google Scholar
Koren, G, Florescu, A, Costei, AM, Boskovic, R, Moretti, ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006; 40: 824–9.Google Scholar
Macones, GA, Robinson, CA. Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol 1997; 177: 819–24.Google Scholar
Macones, GA, Marder, SJ, Clothier, B, Stamilio, DM. The controversy surrounding indomethacin for tocolysis. Am J Obstet Gynecol 2001; 184: 264–72.CrossRefGoogle ScholarPubMed
Ostensen, M, Khamashta, M, Lockshin, M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209.Google Scholar
Ostensen, M, Villiger, PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001;10:135–139. Lupus 2001; 10: 135–9.Google Scholar
Viktil, KK, Engeland, A, Furu, K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41: 196–201.Google Scholar
Moskovitz, DN, Bodian, C, Chapman, ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656–61.Google Scholar
Francella, A, Dyan, A, Bodian, C, Rubin, P, Chapman, M, Present, DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9–17.Google Scholar
Armenti, VT, Coscia, LA, McGrory, CH, Moritz, MJ. National Transplantation Pregnancy Registry. Update on pregnancy and renal transplantation. Nephrol News Issues 1998; 12: 19–23.Google Scholar
Armenti, VT, Moritz, MJ, Davison, JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 219–32.Google Scholar
Norgard, B, Pedersen, L, Christensen, LA, Sorensen, HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406–13.Google Scholar
Bar Oz, B, Hackman, R, Einarson, T, Koren, G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051–5.Google Scholar
Ujhazy, E, Balonova, T, Durisova, M, et al. Teratogenicity of cyclophosphamide in New Zealand white rabbits. Neoplasma 1993; 40: 45–9.Google Scholar
Kirshon, B, Wasserstrum, N, Willis, R, Herman, GE, McCabe, ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72: 462–4.Google Scholar
Enns, GM, Roeder, E, Chan, RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999; 86: 237–41.Google Scholar
Berry, DL, Theriault, RL, Holmes, FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17: 855–61.Google Scholar
Ring, AE, Smith, IE, Jones, A, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23: 4192–7.CrossRefGoogle ScholarPubMed
Ehrenstein, MR, Evans, JG, Singh, A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277–85.Google Scholar
Rychly, DJ, DiPiro, JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005; 25: 1181–92.Google Scholar
Baker, DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord 2004; 4: 196–210.Google Scholar
Mahadevan, U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38: 629–49.Google Scholar
Carter, JD, Ladhani, A, Ricca, LR, Valeriano, J, Vasey, FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635–41.Google Scholar
Crijns, HJ, Jentink, J, Garne, E, et al. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J Rheumatol 2011; 38: 1871–4.Google Scholar
Gisbert, JP, Chaparro, M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426–38.Google Scholar
Clowse, M, Wolf, D, Forger, F, et al. Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes. Arthritis Rheum 2013; 65: S187–8.Google Scholar
Kavanaugh, A, Cush, JJ, Ahmed, MS, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res 2015; 67: 313–25.Google Scholar
Herold, M, Schnohr, S, Bittrich, H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19: 3439.Google Scholar
Friedrichs, B, Tiemann, M, Salwender, H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006; 91: 1426–7.Google Scholar
Buckley, LM, Bullaboy, CA, Leichtman, L, Marquez, M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971–3.Google Scholar
Hyoun, SC, Obican, SG, Scialli, AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol 2012; 94: 187–207.Google Scholar
Sifontis, NM, Coscia, LA, Constantinescu, S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698–702.Google Scholar
Perez-Aytes, A, Ledo, A, Boso, V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008; 146A: 1–7.Google Scholar
Cassina, M, Johnson, DL, Robinson, LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012; 64: 2085–94.Google Scholar
Food and Drug Administration (FDA). Drug approval package: Actemra (tocilizumab) injection, 1/8/2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000TOC.cfm (accessed March 2017).Google Scholar
Kotzin, BL. Systemic lupus erythematosus. Cell 1996; 85: 303–6.Google Scholar
Buckman, KJ, Moore, SK, Ebbin, AJ, Cox, MB, Dubois, EL. Familial systemic lupus erythematosus. Arch Intern Med 1978; 138: 1674–6.Google Scholar
Isenberg, D. Autoantibodies. In Wallace, DJ, Hahn, BH (eds), Dubois’ Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013, p. 282.Google Scholar
Tomer, Y, Viegas, OA, Swissa, M, Koh, SC, Shoenfeld, Y. Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol. 1996; 14: 275–80.Google Scholar
Benito-Garcia, E, Schur, PH, Lahita, R. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004; 51: 1030–44.Google Scholar
Bertoli, AM, Vila, LM, Reveille, JD, Alarcon, GS. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008; 35: 2355–8.Google Scholar
Lee, SS, Singh, S, Link, K, Petri, M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38: 41–54.Google Scholar
Barnes, EV, Narain, S, Naranjo, A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576–82.Google Scholar
Vila, LM, Alarcon, GS, McGwin, G, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005; 32: 2150–5.Google Scholar
Lattanzi, B, Consolaro, A, Solari, N, et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res 2011; 63 (Suppl 11): S112–17.Google Scholar
Ruperto, N, Hanrahan, LM, Alarcon, GS, et al. International consensus for a definition of disease flare in lupus. Lupus 2011; 20: 453–62.Google Scholar
Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.Google Scholar
Petri, M, Orbai, AM, Alarcon, GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–86.Google Scholar
Lech, M, Anders, HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013; 24: 1357–66.Google Scholar
Ortega, LM, Schultz, DR, Lenz, O, Pardo, V, Contreras, GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19: 557–74.Google Scholar
O’Flynn, J, Flierman, R, van der Pol, P, et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol 2011; 49: 75–83.Google Scholar
Waldman, M, Madaio, MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14: 19–24.Google Scholar
Weening, JJ, D’Agati, VD, Schwartz, MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–50.Google Scholar
Wong, KL, Woo, EK, Yu, YL, Wong, RW. Neurological manifestations of systemic lupus erythematosus: a prospective study. Q J Med 1991; 81: 857–70.Google Scholar
Futrell, N, Schultz, LR, Millikan, C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 1992; 42: 1649–57.Google Scholar
Sibley, JT, Olszynski, WP, Decoteau, WE, Sundaram, MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47–52.Google Scholar
Mikdashi, J, Krumholz, A, Handwerger, B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005; 64: 2102–7.Google Scholar
Joseph, FG, Lammie, GA, Scolding, NJ. CNS lupus: a study of 41 patients. Neurology 2007; 69: 644–54.Google Scholar
Hanly, JG, Su, L, Farewell, V, McCurdy, G, Fougere, L, Thompson, K. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009; 36: 1449–59.Google Scholar
Hanly, JG, McCurdy, G, Fougere, L, Douglas, JA, Thompson, K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156–62.Google Scholar
Garenstein, M PV, Kark, RM. Systemic lupus erythematosus and pregnancy. N Engl J Med 1962 ;267: 165–9.Google Scholar
Estes, D LD. Systemic lupus erythematosus and pregnancy. Clin Obstet Gynecol 1965; 8: 307–21.Google Scholar
Lockshin, MD, Reinitz, E, Druzin, ML, Murrman, M, Estes, D. Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 1984; 77: 893–8.Google Scholar
Meehan, RT, Dorsey, JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 1987; 14: 252–8.Google Scholar
Mintz, G, Niz, J, Gutierrez, G, Garcia-Alonso, A, Karchmer, S. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol 1986; 13: 732–9.Google ScholarPubMed
Petri, M, Howard, D, Repke, J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34: 1538–45.Google Scholar
Urowitz, MB, Gladman, DD, Farewell, VT, Stewart, J, McDonald, J. Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392–7.Google Scholar
Ruiz-Irastorza, G, Lima, F, Alves, J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133–8.Google Scholar
Georgiou, PE, Politi, EN, Katsimbri, P, Sakka, V, Drosos, AA. Outcome of lupus pregnancy: a controlled study. Rheumatology 2000; 39: 1014–19.Google Scholar
Kleinman, D, Katz, VL, Kuller, JA. Perinatal outcomes in women with systemic lupus erythematosus. J Perinatol 1998; 18: 178–82.Google Scholar
Johns, KR, Morand, EF, Littlejohn, GO. Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Aust N Z J Med 1998; 28: 18–22.Google Scholar
Derksen, RH, Bruinse, HW, de Groot, PG, Kater, L. Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 1994; 3: 149–55.Google Scholar
Aggarwal, N, Sawhney, H, Vasishta, K, Chopra, S, Bambery, P. Pregnancy in patients with systemic lupus erythematosus. Aust N Z J Obstet Gynaecol 1999; 39: 28–30.Google Scholar
Le Huong, D, Wechsler, B, Vauthier-Brouzes, D, et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol 1997; 36: 772–7.Google Scholar
Lockshin, MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 1989; 32: 665–70.CrossRefGoogle Scholar
Hayslett, JP. Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis 1991; 17: 123–6.Google Scholar
Bobrie, G, Liote, F, Houillier, P, Grunfeld, JP, Jungers, P. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987; 9: 339–43.Google Scholar
Huong, DL, Wechsler, B, Vauthier-Brouzes, D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 2001; 60: 599–604.Google Scholar
Ruiz-Irastorza, G, Khamashta, MA. Lupus and pregnancy: ten questions and some answers. Lupus 2008; 17: 416–20.Google Scholar
Cortes-Hernandez, J, Ordi-Ros, J, Paredes, F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology 2002; 41: 643–50.Google Scholar
Clowse, ME, Magder, L, Witter, F, Petri, M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640–7.Google Scholar
Julkunen, H, Kaaja, R, Palosuo, T, Gronhagen-Riska, C, Teramo, K. Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand 1993; 72: 258–63.Google Scholar
Tandon, A, Ibanez, D, Gladman, DD, Urowitz, MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004; 50: 3941–6.Google Scholar
Wong, KL, Chan, FY, Lee, CP. Outcome of pregnancy in patients with systemic lupus erythematosus: a prospective study. Arch Intern Med 1991; 151: 269–73.Google Scholar
Petri, M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am 1997; 23: 1–13.Google Scholar
Nossent, HC, Swaak, TJ. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. J Rheumatol 1990; 17: 771–6.Google Scholar
Tincani, A, Faden, D, Tarantini, M, et al. Systemic lupus erythematosus and pregnancy: a prospective study. Clin Exp Rheumatol 1992; 10: 439–46.Google ScholarPubMed
Hayslett, JP, Lynn, RI. Effect of pregnancy in patients with lupus nephropathy. Kidney Int 1980; 18: 207–20.Google Scholar
Jungers, P, Dougados, M, Pelissier, C, et al. Lupus nephropathy and pregnancy. Report of 104 cases in 36 patients. Arch Intern Med 1982; 142: 771–6.Google Scholar
Bear, R. Pregnancy and lupus nephritis. A detailed report of six cases with a review of the literature. Obstet Gynecol 1976; 47: 715–18.Google Scholar
Julkunen, H. Pregnancy and lupus nephritis. Scan J Urol Nephrol 2001; 35: 319–27.Google Scholar
Oviasu, E, Hicks, J, Cameron, JS. The outcome of pregnancy in women with lupus nephritis. Lupus 1991; 1: 19–25.Google Scholar
Packham, DK, Lam, SS, Nicholls, K, Fairley, KF, Kincaid-Smith, PS. Lupus nephritis and pregnancy. Q J Med 1992; 83: 315–24.Google Scholar
Moroni, G, Ponticelli, C. Pregnancy after lupus nephritis. Lupus 2005; 14: 89–94.Google Scholar
Moroni, G, Ponticelli, C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003; 16: 161–7.Google Scholar
Ruiz-Irastorza, G, Khamas hta, MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus 2004; 13: 679–82.Google Scholar
Clowse, ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33: 237–52, v.Google Scholar
Bootsma, H, Spronk, P, Derksen, R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595–9.Google Scholar
ter Borg, EJ, Horst, G, Hummel, EJ, Limburg, PC, Kallenberg, CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634–43.Google Scholar
Devoe, LD, Loy, GL. Serum complement levels and perinatal outcome in pregnancies complicated by systemic lupus erythematosus. Obstet Gynecol 1984; 63: 796–800.Google Scholar
Devoe, LD, Taylor, RL. Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol 1979; 135: 473–9.Google Scholar
Buyon, JP, Cronstein, BN, Morris, M, Tanner, M, Weissmann, G. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986; 81: 194–200.Google Scholar
Girardi, G, Salmon, JB. The role of complement in pregnancy and fetal loss. Autoimmunity 2003; 36: 19–26.Google Scholar
Shibata, S, Sasaki, T, Hirabayashi, Y, et al. Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis. Ann Rheum Dis 1992; 51: 619–23.Google Scholar
Lockshin, MD, Qamar, T, Redecha, P, Harpel, PC. Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1467–72.Google Scholar
Adelsberg, BR. The complement system in pregnancy. Am J Reprod Immunol. 1983; 4: 38–44.Google Scholar
Weiner, CP, Brandt, J. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia. Am J Obstet Gynecol 1982; 142: 275–81.Google Scholar
Weiner, CP, Kwaan, HC, Xu, C, Paul, M, Burmeister, L, Hauck, W. Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol 1985; 65: 301–6.Google Scholar
Julkunen, H, Jouhikainen, T, Kaaja, R, et al. Fetal outcome in lupus pregnancy: a retrospective case-control study of 242 pregnancies in 112 patients. Lupus 1993; 2: 125–31.Google Scholar
Nicklin, JL. Systemic lupus erythematosus and pregnancy at the Royal Women’s Hospital, Brisbane 1979–1989. Aus N Z J Obstet Gynaecol 1991; 31: 128–33.Google Scholar
Yasmeen, S, Wilkins, EE, Field, NT, Sheikh, RA, Gilbert, WM. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10: 91–6.Google Scholar
Ramsey-Goldman, R, Kutzer, JE, Kuller, LH, et al. Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus. Am J Edpidemiol 1993; 138: 1057–69.Google ScholarPubMed
Hayslett, JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol 1992; 28: 199–204.Google Scholar
Petri, M, Allbritton, J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993; 20: 650–6.Google Scholar
McHugh, NJ, Reilly, PA, McHugh, LA. Pregnancy outcome and autoantibodies in connective tissue disease. J Rheumatol 1989; 16: 42–6.Google Scholar
Pierce, DA, Stern, R, Jaffe, R, Zulman, J, Talal, N. Immunoblastic sarcoma with features of Sjogren’s syndrome and systemic lupus erythematosus in a patient with immunoblastic lymphadenopathy. Arthritis Rheum 1979; 22: 911–16.Google Scholar
Gimovsky, ML, Montoro, M, Paul, RH. Pregnancy outcome in women with systemic lupus erythematosus. Obstet Gynecol 1984; 63: 686–92.Google Scholar
Clark, CA, Spitzer, KA, Laskin, CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 2005; 32: 1709–12.Google Scholar
Andrade, R, Sanchez, ML, Alarcon, GS, et al. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]. Clin Exp Rheumatol 2008; 26: 268–74.Google Scholar
Imbasciati, E, Surian, M, Bottino, S, et al. Lupus nephropathy and pregnancy. A study of 26 pregnancies in patients with systemic lupus erythematosus and nephritis. Nephron 1984; 36: 46–51.Google Scholar
Lima, F, Khamashta, MA, Buchanan, NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131–6.Google Scholar
Englert, HJ, Derue, GM, Loizou, S, et al. Pregnancy and lupus: prognostic indicators and response to treatment. Q J Med 1988; 66: 125–36.Google Scholar
Siamopoulou-Mavridou, A, Manoussakis, MN, Mavridis, AK, Moutsopoulos, HM. Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset. Ann Rheum Dis 1988; 47: 982–7.Google Scholar
Varner, MW, Meehan, RT, Syrop, CH, Strottmann, MP, Goplerud, CP. Pregnancy in patients with systemic lupus erythematosus. Am J Obstet Gynecol 1983; 145: 1025–40.Google Scholar
Houser, MT, Fish, AJ, Tagatz, GE, Williams, PP, Michael, AF. Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol 1980; 138: 409–13.Google Scholar
Johnson, MJ, Petri, M, Witter, FR, Repke, JT. Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic. Obstet Gynecol 1995; 86: 396–9.Google Scholar
Buyon, JP. Neonatal lupus syndromes. Curr Opin Rheumatol 1994; 6: 523–9.Google Scholar
Lockshin, MD, Bonfa, E, Elkon, K, Druzin, ML. Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 697–701.Google Scholar
Buyon, JP, Hiebert, R, Copel, J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658–66.Google Scholar
Neiman, AR, Lee, LA, Weston, WL, Buyon, JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137: 674–80.Google Scholar
Brucato, A, Doria, A, Frassi, M, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 2002; 11: 716–21.Google Scholar
Llanos, C, Izmirly, PM, Katholi, M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60: 3091–7.Google Scholar
Meisgen, S, Ostberg, T, Salomonsson, S, et al. The HLA locus contains novel foetal susceptibility alleles for congenital heart block with significant paternal influence. J Intern Med 2014; 275: 640–51.Google Scholar
Buyon, JP, Clancy, RM, Friedman, DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5: 139–48.Google Scholar
Friedman, DM, Zervoudakis, I, Buyon, JP. Perinatal monitoring of fetal well-being in the presence of congenital heart block. Am J Perinatol 1998; 15: 669–73.Google Scholar
Jaeggi, ET, Hamilton, RM, Silverman, ED, Zamora, SA, Hornberger, LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution’s experience of 30 years. J AM Coll Cardiol 2002; 39: 130–7.Google Scholar
Izmirly, PM, Saxena, A, Kim, MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124: 1927–35.Google Scholar
Waldman, M, Appel, GB. Update on the treatment of lupus nephritis. Kidney Int 2006; 70: 1403–12.Google Scholar
Rovin, BH, Parikh, SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 2014; 63: 677–90.Google Scholar
Rovin, BH, Parikh, SV, Alvarado, A. The kidney biopsy in lupus nephritis: is it still relevant? Rheum Dis Clin North Am 2014; 40: 537–52, ix.Google Scholar
Melander, C, Sallee, M, Trolliet, P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579–87.Google Scholar
Druzin, ML, Lockshin, M, Edersheim, TG, Hutson, JM, Krauss, AL, Kogut, E. Second-trimester fetal monitoring and preterm delivery in pregnancies with systemic lupus erythematosus and/or circulating anticoagulant. Am J Obstet Gynecol 1987; 157: 1503–10.Google Scholar
Austin, HA, Balow, JE. Treatment of lupus nephritis. Semin Nephrol 2000; 20: 265–76.Google Scholar
Rauova, L, Lukac, J, Levy, Y, Rovensky, J, Shoenfeld, Y. High-dose intravenous immunoglobulins for lupus nephritis: a salvage immunomodulation. Lupus6 2001; 10: 209–13.Google Scholar
Sesso, R, Monteiro, M, Sato, E, et al. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994; 3: 107–12.Google Scholar
Pisoni, CN, Brucato, A, Ruffatti, A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62: 1147–52.Google Scholar
Friedman, DM, Llanos, C, Izmirly, PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62: 1138–46.Google Scholar
Izmirly, PM, Kim, MY, Llanos, C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69: 1827–30.Google Scholar
Izmirly, PM, Costedoat-Chalumeau, N, Pisoni, CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76–82.Google Scholar
Phoon, CK, Kim, MY, Buyon, JP, Friedman, DM. Finding the “PR-fect” solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis 2012; 7: 349–60.Google Scholar
Friedman, DM, Kim, MY, Copel, JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485–93.Google Scholar
Friedman, DM, Kim, MY, Copel, JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103: 1102–6.Google Scholar
Rein, AJ, Mevorach, D, Perles, Z, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009; 119: 1867–72.Google Scholar
Saleeb, S, Copel, J, Friedman, D, Buyon, JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42: 2335–45.Google Scholar
Eliasson, H, Sonesson, SE, Sharland, G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124: 1919–26.Google Scholar
Ruiz-Irastorza, G, Khamashta, MA, Castellino, G, Hughes, GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027–32.Google Scholar
Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006: 4: 295–306.Google Scholar
Blank, M, Cohen, J, Toder, V, Shoenfeld, Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88: 3069–73.Google Scholar
Pierangeli, SS, Harris, EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 1996; 5: 451–5.Google Scholar
Erlendsson, K, Steinsson, K, Johannsson, JH, Geirsson, RT. Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus. J Rheumatol 1993; 20: 1779–85.Google Scholar
Rand, JH, Wu, XX, Andree, HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 997; 337: 154–60.CrossRefGoogle Scholar
Di Simone, N, Meroni, PL, de Papa, N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43: 140–50.Google Scholar
Meroni, PL, Raschi, E, Camera, M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15: 237–40.Google Scholar
Vaarala, O, Alfthan, G, Jauhiainen, M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923–5.Google Scholar
Horkko, S, Miller, E, Dudl, E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. The J Clin Invest 1996; 98: 815–25.Google Scholar
Shi, WT, Forsberg, F, Vaidyanathan, P, Tornes, A, Ostensen, J, Goldberg, BB. The influence of acoustic transmit parameters on the destruction of contrast microbubbles in vitro. Phys Med Biol 2006; 51: 4031–45.Google Scholar
Price, BE, Rauch, J, Shia, MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201–8.Google Scholar
Holers, VM, Girardi, G, Mo, L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211–20.Google Scholar
Berman, J, Girardi, G, Salmon, JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485–90.Google Scholar
Lockwood, CJ, Romero, R, Feinberg, RF, Clyne, LP, Coster, B, Hobbins, JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369–73.Google Scholar
Harris, EN, Spinnato, JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991; 165: 1272–7.Google Scholar
Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498–509.Google Scholar
Galli, M, Luciani, D, Bertolini, G, Barbui, T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32.Google Scholar
Lockshin, MD, Kim, M, Laskin, CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311–18.Google Scholar
Pengo, V, Biasiolo, A. The risk of overdiagnosis of antiphospholipid antibody syndrome. Thromb Haemost 2001; 86: 933.Google Scholar
Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–27.Google Scholar
Andreoli, L, Chighizola, CB, Banzato, A, Pons-Estel, GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 2013; 65: 1869–73.Google Scholar
Bushnell, CD, Goldstein, LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000; 31: 3067–78.Google Scholar
Branch, DW. Antiphospholipid antibodies and pregnancy: maternal implications. Semin Perinatol 1990; 14: 139–46.Google Scholar
Branch, DW, Silver, RM, Blackwell, JL, Reading, JC, Scott, JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614–20.Google Scholar
Levine, JS, Branch, DW, Rauch, J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–63.Google Scholar
Moodley, J, Bhoola, V, Duursma, J, et al. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. S Afr Med J 1995; 85: 105–7.Google Scholar
Bouvier, S, Cochery-Nouvellon, E, Lavigne-Lissalde, G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123: 404–13.Google Scholar
Pauzner, R, Dulitzki, M, Langevitz, P, Livneh, A, Kenett, R, Many, A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001; 86: 1379–84.Google Scholar
Branch, DW, Porter, TF, Rittenhouse, L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001; 184: 825–32.Google Scholar
Branch, DW, Andres, R, Digre, KB, Rote, NS, Scott, JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541–5.Google Scholar
Kupferminc, MJ, Fait, G, Many, A, et al. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96: 45–9.Google Scholar
Lee, RM, Brown, MA, Branch, DW, Ward, K, Silver, RM. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003; 102: 294–300.Google Scholar
Mello, G, Parretti, E, Marozio, L, et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46: 1270–4.Google Scholar
Polzin, WJ, Kopelman, JN, Robinson, RD, Read, JA, Brady, K. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78: 1108–11.Google Scholar
Huong, DL, Wechsler, B, Bletry, O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001; 28: 2025–30.Google Scholar
de Jesus, GR, Agmon-Levin, N, Andrade, CA, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13: 795–813.Google Scholar
Branch, DW, Gibson, M, Silver, RM. Clinical practice. Recurrent miscarriage. N Engl J Med 2010; 363: 1740–7.Google Scholar
Opatrny, L, David, M, Kahn, SR, Shrier, I, Rey, E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33: 2214–21.Google Scholar
Clark, CA, Laskin, CA, Spitzer, KA. Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence. Hum Reprod Update 2012; 18: 474–84.Google Scholar
Silver, RM, Parker, CB, Reddy, UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013; 122: 641–57.Google Scholar
Hanouna, G, Morel, N, Le Thi Huong, D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology 2013; 52: 1635–41.Google Scholar
Asherson, RA, Cervera, R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2003; 5: 395–400.Google Scholar
Asherson, RA, Cervera, R, de Groot, PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530–4.Google Scholar
Camera, A, Rocco, S, De Lucia, D, et al. Reversible adult respiratory distress in primary antiphospholipid syndrome. Haematologica 2000; 85: 208–10.Google Scholar
Cervera, R, Bucciarelli, S, Espinosa, G, et al. Catastrophic antiphospholipid syndrome: lessons from the “CAPS Registry”– a tribute to the late Josep Font. Ann N Y Acad Sci 2007; 1108: 448–56.Google Scholar
Gomez-Puerta, JA, Cervera, R, Espinosa, G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007; 66: 740–6.Google Scholar
Berman, H, Rodriguez-Pinto, I, Cervera, R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12: 1085–90.Google Scholar
Lonze, BE, Singer, AL, Montgomery, RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744–5.CrossRefGoogle Scholar
Bramham, K, Hunt, BJ, Germain, S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19: 58–64.Google Scholar
Farquharson, RG, Quenby, S, Greaves, M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408–13.Google Scholar
Kutteh, WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–9.Google Scholar
Laskin, CA, Spitzer, KA, Clark, CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279–87.Google Scholar
Rai, R, Cohen, H, Dave, M, Regan, L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253–7.Google Scholar
Noble, LS, Kutteh, WH, Lashey, N, Franklin, RD, Herrada, J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684–90.Google Scholar
Stephenson, MD, Ballem, PJ, Tsang, P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 729–34.Google Scholar
Pattison, NS, Chamley, LW, Birdsall, M, Zanderigo, AM, Liddell, HS, McDougall, J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008–12.Google Scholar
Silver, RK, MacGregor, SN, Sholl, JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411–17.Google Scholar
Empson, M, Lassere, M, Craig, J, Scott, J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005 (2): CD002859.Google Scholar
Bates, SM, Greer, IA, Middeldorp, S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S–736S.Google Scholar
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol 2012; 120: 1514–21.Google Scholar
Lefevre, G, Lambert, M, Bacri, JL, et al. Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus 2011; 20: 861–5.Google Scholar
Ruiz-Irastorza, G, Khamashta, MA, Hughes, GR. Heparin and osteoporosis during pregnancy: 2002 update. Lupus 2002; 11: 680–2.Google Scholar
Rodger, MA, Kahn, SR, Cranney, A, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007; 5: 1600–6.Google Scholar
Fausett, MB, Vogtlander, M, Lee, RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185: 148–52.Google Scholar
Arnaud, L, Mathian, A, Ruffatti, A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014; 13: 281–91.Google Scholar
Triolo, G, Ferrante, A, Ciccia, F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728–31.Google Scholar
Branch, DW, Peaceman, AM, Druzin, M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182: 122–7.Google Scholar
Erkan, D, Willis, R, Murthy, VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73: 1176–80.Google Scholar
Costantine, MM, Cleary, K, Eunice Kennedy Shriver National Institute of Child H, Human Development Obstetric–Fetal Pharmacology Research Units N. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121: 349–53.Google Scholar
Horlocker, TT, Wedel, DJ, Rowlingson, JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64–101.Google Scholar
Dugowson, CE, Koepsell, TD, Voigt, LF, et al. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987–1989. Arthritis Rheum 1991; 34: 1502–7.Google Scholar
MacGregor, AJ, Snieder, H, Rigby, AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30–7.Google Scholar
Jawaheer, D, Seldin, MF, Amos, CI, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003; 48: 906–16.Google Scholar
Fisher, SA, Lanchbury, JS, Lewis, CM. Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16. Arthritis Rheum 2003; 48: 1200–6.Google Scholar
Lee, DM, Weinblatt, ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.Google Scholar
Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–81.Google Scholar
Whiting, PF, Smidt, N, Sterne, JA, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152: 456–.Google Scholar
Nelson, JL, Ostensen, M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23: 195–212.Google Scholar
Persellin, RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976; 27: 922–7.Google Scholar
de Man, YA, Dolhain, RJ, van de Geijn, FE, Willemsen, SP, Hazes, JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59: 1241–8.Google Scholar
Oka, M. Effect of pregnancy on the onset and course of rheumatoid arthritis. Ann Rheum Dis 1953; 12: 227–9.Google Scholar
Betson, JR, Dorn, RV. Forty cases of arthritis and pregnancy. J Int Coll Surg 1964; 42: 521–6.Google Scholar
Ostensen, M, Husby, G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 1983; 26: 1155–9.Google Scholar
de Man, YA, Hazes, JM, van der Heide, H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 2009; 60: 3196–206.Google Scholar
Morris, WI. Pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Aus N Z J Obstet Gynaecol 1969; 9: 136–44.Google Scholar
Ostensen, M, Villiger, PM, Forger, F. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun Rev 2012; 11: A437–46.Google Scholar
Brun, JG, Nilssen, S, Kvale, G. Breast feeding, other reproductive factors and rheumatoid arthritis: a prospective study. Br J Rheumatol 1995; 34: 542–6.Google Scholar
Neely, NT, Persellin, RH. Activity of rheumatoid arthritis during pregnancy. Tex Med 1977; 73: 59–63.Google Scholar
Viktil, KK, Engeland, A, Furu, K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy: a population-based cohort study. Pharmacoepidemiol Drug Saf 2009; 18: 737–42.Google Scholar
Chifflot, H, Fautrel, B, Sordet, C, Chatelus, E, Sibilia, J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Seminars in Arthritis Rheum 2008; 37: 223–35.Google Scholar
Steen, VD. Scleroderma and pregnancy. Rheum Dis Clin North Am 1997; 23: 133–47.Google Scholar
LeRoy, EC, Black, C, Fleischmajer, R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.Google Scholar
Reveille, JD, Solomon, DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399–412.Google Scholar
Boin, F, Franchini, S, Colantuoni, E, et al. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009; 60: 2480–9.Google Scholar
Steen, VD. Pregnancy in women with systemic sclerosis. Obstet Gynecol 1999; 94: 15–20.Google Scholar
Steen, VD, Conte, C, Day, N, Ramsey-Goldman, R, Medsger, TA. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989; 32: 151–7.Google Scholar
Knupp, MZ, O’Leary, JA. Pregnancy and scleroderma. Systemic sclerosis. J Fla Med Assoc 1971; 58: 28–30.Google Scholar
Ballou, SP, Morley, JJ, Kushner, I. Pregnancy and systemic sclerosis. Arthritis Rheum 1984; 27: 295–8.Google Scholar
Taraborelli, M, Ramoni, V, Brucato, A, et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum 2012; 64: 1970–7.Google Scholar
Englert, H, Brennan, P, McNeil, D, Black, C, Silman, AJ. Reproductive function prior to disease onset in women with scleroderma. J Rheumatol 1992; 19: 1575–9.Google Scholar
Black, CM. Systemic sclerosis and pregnancy. Baillieres Clin Rheumatol 1990; 4: 105–24.Google Scholar
Silman, AJ, Black, C. Increased incidence of spontaneous abortion and infertility in women with scleroderma before disease onset: a controlled study. Ann Rheum Dis 1988; 47: 441–4.Google Scholar
Chakravarty, EF, Khanna, D, Chung, L. Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet Gynecol 2008; 111: 927–34.Google Scholar
Giordano, M, Valentini, G, Lupoli, S, Giordano, A. Pregnancy and systemic sclerosis. Arthritis Rheum 1985; 28: 237–8.Google Scholar
Kreuter, A, Breuckmann, F, Uhle, A, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50: 740–7.Google Scholar
Braunstein, I, Werth, V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther 2013; 26: 354–63.Google Scholar
Steen, VD. Pregnancy in scleroderma. Rheum Dis Clin North Am 2007; 33: 345–58, vii.Google Scholar
Batocchi, AP, Majolini, L, Evoli, A, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52: 447–52.Google Scholar
Lindstrom, J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: 36–43.Google Scholar
Vincent, A, Newsom-Davis, J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246–52.Google Scholar
Donaldson, JO, Penn, AS, Lisak, RP, et al. Antiacetylcholine receptor antibody in neonatal myasthenia gravis. Am J Dis Child 1981; 135: 222–6.Google Scholar
Plauche, WC. Myasthenia gravis in pregnancy: an update. Am J Obstet Gynecol 1979; 135: 691–7.Google Scholar
Drachman, DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797–810.Google Scholar
Vincent, A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2: 797–804.Google Scholar
Shiraishi, H, Motomura, M, Yoshimura, T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57: 289–93.Google Scholar
Cole, RN, Reddel, SW, Gervasio, OL, Phillips, WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63: 782–9.Google Scholar
Meraouna, A, Cizeron-Clairac, G, Panse RL, , et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006; 108: 432–40.Google Scholar
Luckman, SP, Skeie, GO, Helgeland, G, Gilhus, NE. Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle Nerve 2006; 33: 93–103.Google Scholar
Richman, DP, Agius, MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61: 1652–61.Google Scholar
Zinman, L, Ng, E, Bril, V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837–41.Google Scholar
Buckley, GA, Roberts, DV, Roberts, JB, Thomas, BH, Wilson, A. Drug-induced neonatal myasthenia. Br J Pharmacol 1968; 34: 203P–204P.Google Scholar
Skeie, GO, Apostolski, S, Evoli, A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893–902.Google Scholar
Norwood, F, Dhanjal, M, Hill, M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry 2014; 85: 538–43.Google Scholar
Djelmis, J, Sostarko, M, Mayer, D, Ivanisevic, M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104: 21–5.Google Scholar
Plauche, WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991; 34: 82–99.Google Scholar
McNall, PG, Jafarnia, MR. Management of myasthenia gravis in the obstetrical patient. Am J Obstet Gynecol 1965; 92: 518–25.Google Scholar
Chambers, DC, Hall, JE, Boyce, J. Myasthenia gravis and pregnancy. Obstet Gynecol 1967; 29: 597–603.Google Scholar
Hoff, JM, Daltveit, AK, Gilhus, NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 2003; 61: 1362–6.Google Scholar
Lefvert, AK, Osterman, PO. Newborn infants to myasthenic mothers: a clinical study and an investigation of acetylcholine receptor antibodies in 17 children. Neurology 1983; 33: 133–8.Google Scholar
Bartoccioni, E, Evoli, A, Casali, C, et al. Neonatal myasthenia gravis: clinical and immunological study of seven mothers and their newborn infants. J Neuroimmunol 1986; 12: 155–61.Google Scholar
Brenner, T, Beyth, Y, Abramsky, O. Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci U S A 1980; 77: 3635–9.Google Scholar
Polizzi, A, Huson, SM, Vincent, A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 2000; 62: 332–41.Google Scholar
Levine, SE, Keesey, JC. Successful plasmapheresis for fulminant myasthenia gravis during pregnancy. Arch Neurol 1986; 43: 197–8.Google Scholar
Bader, A. Neurologic and neuromuscular disease. In Chestnut, DH, Wong, CA, Tsen, LC, et al. (eds), Chestnuts’ Obstetric Anesthesia: Principles and Practices, 5th edn. Philadelphia, PA: Elsevier, 2014, p. 1113.Google Scholar
Mao, ZF, Yang, LX, Mo, XA, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 2011; 121: 121–9.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×